[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GT201300167A - Mutantes fc de anticuerpos resistentes a proteasas activas - Google Patents

Mutantes fc de anticuerpos resistentes a proteasas activas

Info

Publication number
GT201300167A
GT201300167A GT201300167A GT201300167A GT201300167A GT 201300167 A GT201300167 A GT 201300167A GT 201300167 A GT201300167 A GT 201300167A GT 201300167 A GT201300167 A GT 201300167A GT 201300167 A GT201300167 A GT 201300167A
Authority
GT
Guatemala
Prior art keywords
mutants
antibodies
active proteases
proteolytic
resistance
Prior art date
Application number
GT201300167A
Other languages
English (en)
Inventor
Randall Brezski
Robert Jordan
William Strohl
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of GT201300167A publication Critical patent/GT201300167A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON LAS REGIONES CONSTANTES DE ANTICUERPOS IGG HUMANA, ESPECIALMENTE LAS REGIONES FC, MUTADAS PARA ALTERAR LOS SITIOS DE CLIVAJE PROTEOLÍTICO QUE CONFIEREN RESISTENCIA A LAS PROTEASAS ENDÓGENAS Y DERIVADAS DE PATÓGENOS Y ADICIONALMENTE ALTERADAS PARA UNIRSE ESPECÍFICAMENTE A LOS RECEPTORES. LAS SECUENCIAS NUEVAS SE PUEDEN INCORPORAR EN COMPOSICIONES DE ANTICUERPOS TERAPÉUTICOS EN DONDE SE DESEA LA RESISTENCIA PROTEOLÍTICA Y LA FUNCIONALIDAD EFECTORA CITOTÓXICA
GT201300167A 2010-12-23 2013-06-21 Mutantes fc de anticuerpos resistentes a proteasas activas GT201300167A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061426619P 2010-12-23 2010-12-23
US201161540882P 2011-09-29 2011-09-29

Publications (1)

Publication Number Publication Date
GT201300167A true GT201300167A (es) 2014-09-26

Family

ID=46314374

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300167A GT201300167A (es) 2010-12-23 2013-06-21 Mutantes fc de anticuerpos resistentes a proteasas activas

Country Status (31)

Country Link
US (2) US8871204B2 (es)
EP (1) EP2654780B1 (es)
JP (1) JP6012624B2 (es)
KR (1) KR101900280B1 (es)
CN (1) CN103260640B (es)
AU (1) AU2011349719B2 (es)
BR (1) BR112013018317A2 (es)
CA (1) CA2822366A1 (es)
CO (1) CO6741179A2 (es)
CR (1) CR20130292A (es)
CY (1) CY1118923T1 (es)
DK (1) DK2654780T3 (es)
EA (1) EA028658B1 (es)
EC (1) ECSP13012712A (es)
ES (1) ES2623912T3 (es)
GT (1) GT201300167A (es)
HR (1) HRP20170595T1 (es)
HU (1) HUE033205T2 (es)
IL (1) IL226987A (es)
LT (1) LT2654780T (es)
MX (1) MX347077B (es)
MY (1) MY162489A (es)
NI (1) NI201300057A (es)
NZ (1) NZ612379A (es)
PL (1) PL2654780T3 (es)
PT (1) PT2654780T (es)
RS (1) RS55906B1 (es)
SG (1) SG191233A1 (es)
SI (1) SI2654780T1 (es)
WO (1) WO2012087746A1 (es)
ZA (1) ZA201305538B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618292T3 (es) 2008-01-31 2017-06-21 Inserm - Institut National De La Sante Et De La Recherche Medicale Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
PL2654780T3 (pl) * 2010-12-23 2017-07-31 Janssen Biotech, Inc Aktywne mutanty przeciwciała fc odporne na proteazy
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
AU2012275287B2 (en) 2011-06-28 2017-10-05 Inhibrx, Inc. Serpin fusion polypeptides and methods of use thereof
AU2013218017B2 (en) 2012-02-07 2017-12-07 Innate Pharma MICA binding agents
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
EP3169703B2 (en) * 2014-07-16 2023-12-13 Hinrich Abken Chimeric antigen receptor and its use
CN104177496B (zh) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 人IgG2抗体铰链区修饰体
WO2016131950A1 (en) 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
EP3736294A3 (en) 2014-10-10 2021-02-17 Innate Pharma Cd73 blockade
CA2965151A1 (en) * 2014-10-27 2016-05-06 Brendan P. Eckelman Serpin fusion polypeptides and methods of use thereof
EP3221359B1 (en) 2014-11-17 2020-05-27 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
US10196445B1 (en) 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
EP3302532A4 (en) 2015-06-05 2019-01-09 New York University COMPOSITIONS AND METHODS RELATED TO ANTISTAPHYLOCOCCAL BIOLOGICAL AGENTS
AU2016297862C1 (en) 2015-07-24 2022-12-15 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding
CN107921128B (zh) 2015-08-05 2022-04-26 詹森生物科技公司 抗cd154抗体及其使用方法
MA43053A (fr) 2015-09-30 2018-08-08 Janssen Biotech Inc Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
CN108368511B (zh) * 2015-10-23 2022-12-06 阿珀吉科吉尼科斯股份公司 单链cd137受体激动剂蛋白
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
MX2018011035A (es) 2016-03-15 2019-01-17 Innate Pharma Anticuerpos-anti-mica.
SG10202011624SA (en) * 2016-05-23 2021-01-28 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
EP3470424A4 (en) * 2016-06-08 2020-03-04 Shanghai Jiaotong University School of Medicine SEQUENCE OF HEAVY CHAIN CONSTANT ANTIBODY REGION TO INCREASE AGONIST-ANTIBODY ACTIVITY
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
MX2019010848A (es) 2017-03-16 2019-10-30 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
CN110546162B (zh) * 2017-03-28 2021-09-07 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
WO2018207023A2 (en) * 2017-05-10 2018-11-15 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
DK3456736T3 (da) 2017-09-19 2021-05-03 Tillotts Pharma Ag Antistofvarianter
KR20210023983A (ko) 2018-06-18 2021-03-04 이나뜨 파르마 암을 치료하기 위한 조성물 및 방법
MA53495A (fr) 2018-08-31 2021-12-08 Regeneron Pharma Stratégie de dosage permettant d'atténuer le syndrome de libération de cytokines pour des anticorps bispécifiques cd3/c20
BR112021005907A2 (pt) 2018-09-27 2021-08-10 Xilio Development, Inc. citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
US20220169706A1 (en) * 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
WO2021041336A1 (en) * 2019-08-23 2021-03-04 City Of Hope Igg antibody compositions and methods of making the same
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
TW202221016A (zh) * 2020-08-07 2022-06-01 美商建南德克公司 Ｆｌｔ３配位體融合蛋白及使用方法
US20240294605A1 (en) * 2021-02-04 2024-09-05 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
CN117597365A (zh) * 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
KR20240123827A (ko) 2021-12-16 2024-08-14 상하이 바오 파마슈티컬스 컴퍼니 리미티드 항면역글로불린 분해 효소에 의해 효소 절단된 Fc 변이체
US12091694B2 (en) 2022-11-18 2024-09-17 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
US12129499B2 (en) 2023-01-06 2024-10-29 Seismic Therapeutic, Inc. Protease variants and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
EP1082137A4 (en) 1998-05-06 2004-05-19 Univ Temple REVERSE OF PERCENTAL RESPONSE BY INTERRUPTING THE MACROPHAGE RECEPTOR FcSg (g) RI
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
JP4368530B2 (ja) 1999-04-09 2009-11-18 協和発酵キリン株式会社 免疫機能分子の活性を調節する方法
US7129331B2 (en) 2000-05-31 2006-10-31 Pestka Biomedical Laboratories, Inc. Phosphorylated polypeptides and uses related thereto
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2592015A1 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
EP1937306B1 (en) 2005-08-19 2016-02-17 Janssen Biotech, Inc. Proteolysis resistant antibody preparations
AU2006299429B2 (en) * 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
ES2593791T3 (es) * 2007-08-10 2016-12-13 Janssen Biotech, Inc. Fragmentos de clivaje inmunoglobulina utilizados como indicadores de enfermedades y aglutinante de fijación
MY163473A (en) * 2007-09-26 2017-09-15 Chugai Pharmaceutical Co Ltd Modified antibody constant region
EP2205258B1 (en) 2007-09-28 2017-05-24 Janssen Biotech, Inc. Methods and structural conformations of antibody preparations with increased resistance to proteases
AU2008311815B2 (en) * 2007-10-19 2014-02-06 Seagen Inc. CD19 binding agents and uses thereof
CA2758524A1 (en) 2009-04-21 2010-10-28 Amgen Inc. Fragmentation resistant igg1 fc-conjugates
PL2654780T3 (pl) * 2010-12-23 2017-07-31 Janssen Biotech, Inc Aktywne mutanty przeciwciała fc odporne na proteazy
US8729985B2 (en) 2012-01-23 2014-05-20 Electro-Mechanical Corporation Switchgear visible disconnect mechanical interlock

Also Published As

Publication number Publication date
NI201300057A (es) 2014-02-25
CA2822366A1 (en) 2012-06-28
LT2654780T (lt) 2017-03-27
AU2011349719B2 (en) 2016-09-15
IL226987A (en) 2017-07-31
CO6741179A2 (es) 2013-08-30
KR101900280B1 (ko) 2018-11-08
EA028658B1 (ru) 2017-12-29
MY162489A (en) 2017-06-15
ECSP13012712A (es) 2013-08-30
AU2011349719A1 (en) 2013-07-04
CN103260640A (zh) 2013-08-21
JP2014504301A (ja) 2014-02-20
HUE033205T2 (en) 2017-11-28
CY1118923T1 (el) 2018-01-10
US20130011386A1 (en) 2013-01-10
EP2654780B1 (en) 2017-02-01
MX2013007291A (es) 2013-09-13
WO2012087746A1 (en) 2012-06-28
EP2654780A1 (en) 2013-10-30
SG191233A1 (en) 2013-07-31
MX347077B (es) 2017-04-10
JP6012624B2 (ja) 2016-10-25
NZ612379A (en) 2014-10-31
KR20140003485A (ko) 2014-01-09
PL2654780T3 (pl) 2017-07-31
CN103260640B (zh) 2015-12-02
DK2654780T3 (en) 2017-04-10
US9611328B2 (en) 2017-04-04
CR20130292A (es) 2013-10-03
HRP20170595T1 (hr) 2017-06-16
US20150139984A1 (en) 2015-05-21
EA201390958A1 (ru) 2013-11-29
PT2654780T (pt) 2017-04-06
RS55906B1 (sr) 2017-09-29
BR112013018317A2 (pt) 2017-03-21
ES2623912T3 (es) 2017-07-12
EP2654780A4 (en) 2015-03-18
SI2654780T1 (sl) 2017-06-30
US8871204B2 (en) 2014-10-28
ZA201305538B (en) 2015-01-28

Similar Documents

Publication Publication Date Title
GT201300167A (es) Mutantes fc de anticuerpos resistentes a proteasas activas
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CO2020003714A2 (es) Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostéricos
CY1121076T1 (el) Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες
PE20200617A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39
CL2019001745A1 (es) Conjugados anticuerpo droga para ablacion de celulas madre hematopoyeticas.
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
PE20201419A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
BR112015030514A2 (pt) Composições e métodos para conjugação de anticorpos ativáveis
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
GT201200318A (es) Anticuerpos hacia gdf8 humano
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
TR201908761T4 (tr) Antidll3-antikor-pbd konjugatları ve kullanımları.
EA201101530A1 (ru) ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
AR083044A1 (es) Anticuerpos anti-cd48 y usos de los mismos
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
GT201200109A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos